Acquired Bleeding Disorder Clinical Trial
Official title:
Safety of Eptacog Alfa (Activated) (Genetical Recombination) on Adverse Events and Serious Adverse Events in Patients With Acute Intracerebral Haemorrhage.
Verified date | November 2016 |
Source | Novo Nordisk A/S |
Contact | n/a |
Is FDA regulated | No |
Health authority | Japan: Ministry of Health, Labor and Welfare |
Study type | Interventional |
This trial is conducted in Japan. The purpose of this trial is to evaluate the safety and preliminary efficacy of Activated Recombinant Factor VII (NN-007) in patients with acute intracerebral haemorrhage.
Status | Completed |
Enrollment | 90 |
Est. completion date | April 2007 |
Est. primary completion date | April 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - Spontaneous ICH Exclusion Criteria: - Time of ICH onset > 3 hours - Patients with secondary ICH - Pre-existing disability - Hemophilia |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Japan | Novo Nordisk Investigational Site | Tokyo |
Lead Sponsor | Collaborator |
---|---|
Novo Nordisk A/S |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Occurrence of thromboembolic serious adverse event | Until 90 days | No | |
Secondary | Reducing disability and improving clinical outcome | No | ||
Secondary | Reducing haematoma growth | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01601457 -
Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction
|
Phase 2 | |
Completed |
NCT00124293 -
Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury
|
N/A | |
Terminated |
NCT00184548 -
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding
|
Phase 3 | |
Completed |
NCT02239146 -
Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass
|
Phase 1 | |
Completed |
NCT01563445 -
Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage
|
Phase 2 | |
Withdrawn |
NCT00323570 -
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma
|
Phase 3 | |
Completed |
NCT00127283 -
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
|
Phase 3 | |
Completed |
NCT01563523 -
Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients
|
Phase 2 | |
Terminated |
NCT01564563 -
Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Completed |
NCT01153997 -
Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers
|
Phase 1 | |
Completed |
NCT00697320 -
Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany
|
N/A | |
Completed |
NCT00914589 -
Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery
|
Phase 2 | |
Completed |
NCT00102037 -
Use of Activated Recombinant FVII in Spinal Surgery
|
Phase 2 | |
Completed |
NCT01562821 -
Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy
|
Phase 2 | |
Completed |
NCT01601613 -
Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever
|
Phase 2 | |
Completed |
NCT00123591 -
Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury
|
Phase 2 | |
Completed |
NCT01562574 -
Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease
|
Phase 3 | |
Completed |
NCT01285089 -
Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With Acquired Haemophilia
|
N/A | |
Terminated |
NCT00154427 -
Use of Activated Recombinant Human Factor VII in Cardiac Surgery
|
Phase 2 | |
Completed |
NCT00426803 -
Recombinant Factor VIIa in Acute Intracerebral Haemorrhage
|
Phase 2 |